Pancreatic Cancer Treatment in Hyderabad

Overview

Understanding Pancreatic Cancer

Pancreatic cancer is one of the most challenging malignancies in abdominal oncology — often diagnosed late because early-stage disease produces no symptoms, and the pancreas lies deep in the retroperitoneum, difficult to reach on clinical examination. The majority of cases are pancreatic ductal adenocarcinoma (PDAC), although neuroendocrine tumours (PNETs) represent a more indolent subtype.

Surgery remains the only potentially curative treatment for pancreatic cancer. The challenge is that at diagnosis, only 15–20% of patients have resectable disease. The remainder are locally advanced (involving major vessels) or metastatic. However, “borderline resectable” disease is not a verdict — with well-chosen neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine+nab-paclitaxel), a meaningful proportion can be downstaged to surgery.

In my practice, I assess every patient for resectability using dedicated pancreatic protocol CT, and in borderline cases, I present the case at a multidisciplinary tumour board before recommending a management plan. No patient should be told “inoperable” without a specialist evaluation.

At a Glance

Most common type: Pancreatic ductal adenocarcinoma (PDAC) — 85%
Location: Head of pancreas (70%), body/tail (30%)
Key staging: Resectable, borderline resectable, locally advanced, metastatic
Curative surgery: Whipple’s procedure or distal pancreatectomy
5-year survival (resected): 20–25% for PDAC; significantly higher for PNETs

Warning Signs

Symptoms of Pancreatic Cancer

Most symptoms appear late and are non-specific — any of these in combination should prompt urgent investigation.

💛
Painless Jaundice

Yellow skin and eyes from bile duct obstruction — the most common presentation for head tumours.

⚖️
Weight Loss

Significant, unintentional weight loss often accompanied by loss of appetite.

🔥
Upper Abdominal Pain

Dull, persistent mid-epigastric or back pain — often worse lying flat, better leaning forward.

🩸
New-Onset Diabetes

Unexplained new diabetes in a non-obese adult over 50 warrants pancreatic evaluation.

🤢
Nausea & Vomiting

Caused by gastric outlet obstruction or tumour effects on the digestive process.

🩺
Incidental Finding

Small tumours discovered incidentally on CT done for other reasons — increasingly common.

Our Approach

Surgical Approach to Pancreatic Cancer

For cancer of the head of pancreas, the Whipple’s procedure (pancreaticoduodenectomy) removes the head of the pancreas, duodenum, gallbladder, and part of the bile duct, followed by reconstruction. It is one of the most complex operations in abdominal surgery, but in experienced hands, carries a mortality of under 3% and an acceptable morbidity.

For body and tail tumours, a distal pancreatectomy with splenectomy is performed — increasingly feasible laparoscopically. For borderline resectable disease, I work with oncologists to plan neoadjuvant chemotherapy first, then reassess for surgery after 3–6 months. The goal is always to achieve a clear (R0) surgical margin — this is the single most important prognostic factor.

Post-operatively, patients are managed with an enhanced recovery protocol: early ambulation, oral feeding from day 1–2, and proactive management of the most common complications — pancreatic fistula and delayed gastric emptying. Most patients are discharged within 7–10 days.

Surgical Procedure
Whipple’s Procedure (Pancreaticoduodenectomy)

Complex resection of the pancreatic head, duodenum, and bile duct — the standard curative surgery for head of pancreas cancer.

Learn more →

Surgical Procedure
HIPEC for Pancreatic Peritoneal Spread

Heated intraperitoneal chemotherapy for selected patients with limited peritoneal involvement from pancreatic cancer.

Learn more →

Why Choose Us

Expertise You Can Trust

Dr. Mohammed Imaduddin brings internationally trained surgical skills and a patient-first philosophy to every case.

500+
Complex Oncological Surgeries Performed
15+
Years in Surgical Oncology
3
International Training Centres (Hannover, Charité, AIIMS)
FACS
Fellow of the American College of Surgeons

Common Questions

Frequently Asked Questions

Important questions I hear from patients and families navigating a pancreatic cancer diagnosis.

Is pancreatic cancer always inoperable?
No — approximately 15–20% of patients have resectable disease at diagnosis, and a further 20% have borderline resectable disease that may become resectable with neoadjuvant chemotherapy. It is critically important that every patient is evaluated by a specialist in pancreatic surgery before accepting an “inoperable” verdict. I have operated on patients who were told elsewhere that surgery was not possible.
What is the difference between resectable, borderline, and locally advanced?
“Resectable” means the tumour does not involve major blood vessels (SMV, SMA, portal vein, celiac axis) and surgery can achieve clear margins. “Borderline resectable” means there is abutment (<180°) of major vessels — surgery is possible but technically demanding. "Locally advanced" means encasement (>180°) of major vessels — surgery requires vascular reconstruction or is not feasible. These distinctions are made on dedicated CT pancreatic protocol imaging.
What is the Whipple’s procedure recovery like?
The Whipple’s operation typically takes 5–7 hours. Hospital stay is 7–10 days. Recovery takes 6–8 weeks before return to normal activity. Common post-operative challenges include delayed gastric emptying (feeling full, unable to eat normally) in 20–30% of patients, and pancreatic fistula in 10–15%. Most resolve with conservative management. Patients will also need pancreatic enzyme supplementation lifelong.
Should I get chemotherapy before or after surgery?
For clearly resectable disease, the standard approach is surgery first, followed by adjuvant chemotherapy (modified FOLFIRINOX for 6 months). For borderline resectable disease, neoadjuvant chemotherapy first (3–6 months) to shrink the tumour and test the biology, then restaging and surgery if appropriate. This decision is best made in a multidisciplinary tumour board.
What are PNETs and are they different from regular pancreatic cancer?
Pancreatic neuroendocrine tumours (PNETs) are a distinct group of tumours arising from hormone-producing cells of the pancreas. They are generally much more slow-growing than PDAC, and even when metastatic, patients can survive many years. Surgery is the cornerstone of treatment even in metastatic disease for symptom control and improved survival. Do not let a diagnosis of “pancreatic cancer” cause panic — verify the exact pathology first.

Ready to Discuss Your Case?

Every cancer journey is different. I offer a detailed, unhurried consultation to help you understand your options and make informed decisions.

Book via WhatsApp
View Clinic Locations